Significant Milestone Achieved – 80 Serialization Installations Across Our Global Supply Network
We’ve extended our industry leading position for product security for global medicines with significant Serialization and Anticounterfeiting technology investment
We are celebrating a significant milestone in the protection of global drug products with the installation of our 80th Serialization line, further extending our advanced position across our global supply network. Considered an industry leader in product security for global medicines through advanced Serialization and Anticounterfeiting technologies, we continue to invest heavily in services advancing the commercialization of therapies destined to domestic and global markets, supporting medicines destined to more than 100 countries around the world.
Our preparedness for global product security requirements has spanned more than seven years, with support for products meeting the US Drug Supply Chain Security Act (DSCSA), European Union’s Falsified Medicines Directive (FMD), as well as in-country requirements in emerging markets including South Korea, Russia, China, Brazil, Saudi Arabia, and Turkey amongst others. With our expert architecture, clients enjoy singular connectivity to access the entirety of PCI’s extensive global supply network in delivering Serialized medicines with integrated overt and covert Anticounterfeiting protection features.
“It’s been a long journey” notes Brad Payne, Senior Vice President of Global Operations. “At the earliest stages of our preparedness, we leveraged our knowledge and looked to implement a strategy that focused on the industry leading experience for our customers, pairing the best technologies while maximizing ease of use, all with an eye towards allowing for scalability – knowing that at some point we would see the market finally reach maturity in terms of firm governmental requirements and a common framework. Considerable credit needs to be given to organizations like GS1 for the work they have done in working to develop some market standards. The industry still has a ways to go in coalescing around a truly common standard, but PCI has been able to leverage an adaptable solution that allows us to meet the requirements of established markets as well as those countries which are still in flux with shifting or developing standards. The biopharmaceutical industry is truly a global business and we are helping clients meet the requirements for all markets around the world, ensuring safe and effective supplies of lifesaving medicines for all patients.”
In addition to industry leading investment in Serialization and Anticounterfeiting capability, we have made a number of noteworthy acquisitions over the past 12 months, further expanding our global reach and supply network. We have added new facilities in San Diego, California and Dublin, Ireland, as well as Melbourne, Australia in support of global drug supply for both commercial medicines as well as investigational clinical trial medicines. With an integrated molecule-to-market service offering including drug development, scalable drug manufacture, clinical trial packaging and labelling, storage and distribution, as well as commercial packaging services, we have now expanded to eight sites comprised of 20 facilities, supported by more than 3,500 highly trained associates.
October 29, 2018